Certified by Founder
Lodge
Kinaset Therapeutics
start up
- 13/01/2026
- Series B
- $103,000,000
At Kinaset Therapeutics, we intend to develop novel respiratory therapeutics that can positively impact people affected by intractable diseases. Our novel lead asset and experienced team combine a potentially best in class approach to treating severe asthma
- Industry Pharmaceutical Manufacturing
- Website https://www.kinasettherapeutics.com/
- LinkedIn https://www.linkedin.com/company/kinaset-tx/
Iceotope | $26,000,000 | (May 15, 2026)
Harken Sweets | Undisclosed Amount | (May 15, 2026)
Graphon AI | $8,300,000 | (May 15, 2026)
Ranger AI | $8,400,000 | (May 15, 2026)
Wirestock | $23,000,000 | (May 15, 2026)
GridCARE | $64,000,000 | (May 15, 2026)
Chromie Health | $2,000,000 | (May 15, 2026)
Novella | $21,000,000 | (May 15, 2026)
Flick | $6,000,000 | (May 15, 2026)
Synthetic | $10,000,000 | (May 14, 2026)
SwishX | $2,200,000 | (May 14, 2026)
Urologic Health | $11,000,000 | (May 14, 2026)